Key Highlights
- Obexelimab met the primary endpoint, demonstrating a highly statistically significant and clinically meaningful 56% reduction in the risk of IgG4-RD flare compared to placebo during the 52-week randomized placebo-controlled period.
- Don't Miss: Fast Company Calls It a ‘Groundbreaking Step for the Creator Economy' — Investors Can Still Get In at $0.85/Share GM-Backed EnergyX Is Solving the Lithium Supply Crisis — Invest Before They Scale Global Production Obexelimab also met and demonstrated highly statistically significant activity compared to placebo on all four key secondary endpoints, which were reduction in investigator-assessed IgG4-RD flare, the number of flares requiring rescue therapy, the proportion of patients achieving complete remission, and the cumulative use of IgG4-RD rescue therapy.
- Rates of infections, including Grade 3, were lower in the obexelimab arm compared to placebo, and the incidence of injection site reactions was similar across both study arms.
- The company expects that full data from the INDIGO trial will be presented at a future medical meeting.
- Despite touting encouraging data from the pivotal trial, Zenas BioPharma stock is trading lower.
